Ningbo Menovo Pharmaceutical Co., Ltd. (SHA:603538)

Market Cap	3.69B
Revenue (ttm)	1.39B
Net Income (ttm)	73.99M
Shares Out	219.83M
EPS (ttm)	0.34
PE Ratio	49.53
Forward PE	22.08
Dividend	0.05 (0.29%)
Ex-Dividend Date	Jun 25, 2025

Volume	25,637,567
Average Volume	22,162,681
Open	16.76
Previous Close	16.78
Day's Range	16.76 - 18.46
52-Week Range	9.99 - 20.53
Beta	0.25
RSI	58.43
Earnings Date	Aug 29, 2025

About SHA:603538

Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company’s products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal tract, and other therapeutic areas. Ningbo Menovo Pharmaceutical Co., Ltd. was founded in 2004 and is headquartered in Ningbo, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2004
• Employees: 2,472
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603538

Financial Performance

In 2024, SHA:603538's revenue was 1.37 billion, an increase of 12.85% compared to the previous year's 1.22 billion. Earnings were 66.81 million, an increase of 476.64%.